Question special

The stratified randomization is indeed important and useful. However, given the multiple data from trials such as AVOID (Air Versus Oxygen in STEMI), do you think it would be useful to review your retrospective analysis of the patient's baseline characteristics to determine if there was a significant difference in the number of patients with MI (whether it was simply demand ischemia or not)?

I understand that the DETO2X-AMI trials didn't show hard end point differences, but I am sure your patient population is different enough and given the severity of the disease process of ARDS, it is worth looking into whether or not there was a significant difference in terms of the cardiac diseases in each arm of your trial.